PHARMExcel celebrates 13 successful years!
This month PHARMExcel reaches yet another milestone as it celebrates 13 years of successful business.
This month PHARMExcel reaches yet another milestone as it celebrates 13 years of successful business.
This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.
Following its reputation of excellence in delivering investigator-led studies, PHARMExcel was selected to manage the Covid-19 vaccine booster study.
Meet Krishna Askoolam, Clinical Trials Administrator: “This is my first role fresh out of University having graduated with a First-Class Honours degree in Biochemistry from the University of Kent…”
The new EU clinical trial regulation (CTR) is set to revolutionise clinical trial processes across Europe impacting all European Member states and organisations wanting to run clinical trials across these regions. How can organisations prepare for the change and set themselves up successfully with a new CTR programme?
Meet Martha Nabunjo Clinical Research Associate I (Clinical Monitor) “I’ve worked at PHARMExcel almost a year now and I must say in this short space of time, I am very lucky to have had the opportunity to work on some very high-profile studies. What I enjoy most about my role here is that every day…
We are pleased to say that 2021 has seen PHARMExcel busier than ever. From delivering the Worlds’ first Booster Vaccine clinical trial leading to the shaping of UK Government policy, to welcoming new, key staff appointments and undertaking several charity events for Macmillan Cancer Support, Team PHARMExcel showed dedication to the cause. As we complete…